Advanced ALK-EML4 fusion-positive non-small cell lung cancer with intraspinal metastases: a case report. (PubMed, Front Oncol) - Sep 19, 2026 - "However, next-generation sequencing performed at the third recurrence confirmed the presence of the ALK-EML4 fusion mutation. Following the fifth disease recurrence, the patient received palliative radiotherapy followed by combination targeted therapy with lorlatinib and anlotinib, and subsequently transitioned to maintenance therapy with lorlatinib, achieving an overall survival of 121 months (right-censored, t+) and a duration of treatment of 48 months (t+) with lorlatinib as fifth-line therapy."
Journal • Back Pain • CNS Disorders • Lumbar Back Pain • Lung Adenocarcinoma • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • ALK • EGFR • EML4
|
|
Baoyu Guo; Juan Lang; Qi Han; Zhongkui Xiong
|